Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy    crawled time : 00:00    save search
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Published: 2024-04-08 (Crawled : 00:00) - biospace.com/
PSTX | $2.02 1.0% 0.99% 640K twitter stocktwits trandingview |
Health Technology
 | | O: -0.67% H: 0.0% C: 0.0%
car-t therapeutics potential therapy
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K twitter stocktwits trandingview |
Health Technology
 | | O: -0.26% H: 0.0% C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M twitter stocktwits trandingview |
Health Technology
 | | O: 0.49% H: 0.84% C: -0.07%
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
 | | O: 1.06% H: 0.0% C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M twitter stocktwits trandingview |
Health Technology
 | | O: -0.09% H: 1.42% C: 1.1%
ibi310 first cancer colon therapy study
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Published: 2024-03-20 (Crawled : 00:00) - biospace.com/
ACLX | $51.67 -5.19% -5.48% 740K twitter stocktwits trandingview |
| | O: -0.14% H: 1.33% C: 0.75%
conference cell therapy
Manufacturing Approach in Cell Therapy as a Strategic Advantage
Published: 2024-01-17 (Crawled : 00:00) - poseida.com
PSTX | $2.02 1.0% 0.99% 640K twitter stocktwits trandingview |
Health Technology
 | | O: -1.06% H: 5.71% C: 1.79%
advantage cell therapy
Exploring the Unique Advantages of Group Therapy
Published: 2024-01-03 (Crawled : 00:00) - lifestance.com
FNCTF | News | $11.0354 -20.84% 320 twitter stocktwits trandingview |
Communications
 | Email alert Add to watchlist
unique group therapy
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Published: 2023-12-28 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K twitter stocktwits trandingview |
Health Technology
 | | O: 0.28% H: 0.0% C: -1.32%
LLY | News | $726.31 -2.63% -0.04% 3.5M twitter stocktwits trandingview |
Health Technology
 | | O: 0.08% H: 0.81% C: -0.19%
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
 | | O: 0.52% H: 0.72% C: -0.34%
INCY | $52.3 -0.98% -0.99% 2.2M twitter stocktwits trandingview |
Health Technology
 | | O: 0.35% H: 1.07% C: -0.27%
candidate tumors collaboration trial advanced china therapy
Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K twitter stocktwits trandingview |
Health Technology
 | | O: 0.5% H: 1.67% C: 0.1%
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
 | | O: 2.15% H: 0.0% C: 0.0%
mze001 disease license collaboration therapeutics potential agreement therapy sanofi
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
Published: 2023-12-11 (Crawled : 00:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M twitter stocktwits trandingview |
Health Technology
 | | O: 0.77% H: 1.52% C: 0.58%
yescarta t-cell response therapy
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
Published: 2023-11-29 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K twitter stocktwits trandingview |
Manufacturing
 | | O: 0.66% H: 0.0% C: -0.16%
PFE A | $26.0 2.4% -0.15% 38M twitter stocktwits trandingview |
Health Technology
 | | O: 0.76% H: 0.66% C: 0.53%
women therapy hormone
GE HealthCare Announces New Innovations and Collaborations in Image Guided Therapy as part of TCT2023 Cardiology Care Pathway Showcase
Published: 2023-10-23 (Crawled : 00:00) - biospace.com/
GEHC | $84.47 -0.59% -0.59% 1.9M twitter stocktwits trandingview |
n/a
 | | O: -0.16% H: 0.92% C: 0.06%
tct2023 care cardiology therapy
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis
Published: 2023-10-17 (Crawled : 00:00) - biospace.com/
NKTX | $7.26 -6.8% -7.3% 730K twitter stocktwits trandingview |
Health Technology
 | | O: -0.68% H: 168.71% C: 113.61%
partnership lupus natural cell therapeutics therapy
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
Published: 2023-08-29 (Crawled : 00:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K twitter stocktwits trandingview |
Health Technology
 | | O: 5.14% H: 3.21% C: 1.93%
cancer designation china therapy
Compression therapy market to grow by USD 1.24 billion from 2022 to 2027 | Growth driven by increasing prevalence of chronic venous diseases and lymphedema - Technavio
Published: 2023-08-17 (Crawled : 00:00) - prnewswire.com
MDT | $79.48 0.37% -0.29% 6.7M twitter stocktwits trandingview |
Health Technology
 | | O: -1.02% H: 0.0% C: 0.0%
therapy growth market
Addimmune, a Clinical Stage Hiv-Focused Gene Therapy Company, to go Public Through Business Combination With 10x Capital Venture Acquisition Corp. III – Yahoo Finance
Published: 2023-08-09 (Crawled : 00:00) - spacfeed.com
VCXB | $10.99 1.01% -0.18% 16K twitter stocktwits trandingview |
| | O: 0.19% H: 0.0% C: -0.01%
VCXA 4 | $6.5565 -12.61% 63.5% 0 twitter stocktwits trandingview |
| | O: 0.0% H: 0.39% C: 0.39%
DWAC | $49.95 7.47% 22M twitter stocktwits trandingview |
| | O: 4.44% H: 7.74% C: 5.33%
business acquisition therapy
Global Allogeneic Cell Therapy Market Report 2023-2035: Celularity, Allogene Therapeutics, and Fate Therapeutics Driving Innovation, Heralding a New Era in Regenerative Medicine
Published: 2023-08-08 (Crawled : 00:00) - prnewswire.com
CORBF | $1.25 -16.67% 2.4K twitter stocktwits trandingview |
n/a
 | | O: -9.4% H: 14.15% C: 14.15%
SNY | News | $46.32 2.05% 2.01% 3.3M twitter stocktwits trandingview |
Health Technology
 | | O: 0.81% H: 0.0% C: 0.0%
ICLR | $288.32 -1.2% -1.21% 640K twitter stocktwits trandingview |
Health Technology
 | | O: 1.48% H: 0.52% C: -0.63%
report cell global therapeutics therapy market
Testosterone Replacement Therapy Market to Reach $2.22 Billion by 2027, Driven by Rising Testosterone Deficiency Cases
Published: 2023-07-25 (Crawled : 00:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M twitter stocktwits trandingview |
Health Technology
 | | O: -0.34% H: 0.69% C: -0.05%
ABBV | $166.41 1.06% 0.0% 5.5M twitter stocktwits trandingview |
Health Technology
 | | O: -0.62% H: 0.0% C: 0.0%
reach therapy market
REXULTI (brexpiprazole): Approved as Adjunctive Therapy to Treat Adults with MDD and Schizophrenia - Drug Insights and Market Forecasts to 2032 - Focus on 7 Major Markets
Published: 2023-07-20 (Crawled : 00:00) - prnewswire.com
ALSMY | News | $1.57 -1.78% 410K twitter stocktwits trandingview |
Manufacturing
 | | O: 1.35% H: 0.0% C: -0.33%
drug approved treat schizophrenia therapy market
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
Published: 2023-07-20 (Crawled : 00:00) - globenewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: -0.65% H: 0.49% C: 0.07%
LLY | News | $726.31 -2.63% -0.04% 3.5M twitter stocktwits trandingview |
Health Technology
 | | O: 0.35% H: 2.21% C: 1.9%
HCM | $16.49 0.8% 0.79% 61K twitter stocktwits trandingview |
Health Technology
 | | O: -0.33% H: 2.55% C: 1.4%
treatment designation china therapy study
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
Published: 2023-07-13 (Crawled : 00:00) - biospace.com/
VTGN | $4.77 1.49% 1.47% 150K twitter stocktwits trandingview |
Health Technology
 | | O: 1.16% H: 4.0% C: 2.86%
av-101 patent disease levodopa treatment parkinson’s therapy
FDA Approves ARUP Laboratories' AAV5 DetectCDx™, a First-Ever Companion Diagnostic Immunoassay for a Gene Therapy
Published: 2023-06-30 (Crawled : 00:00) - prnewswire.com
BMRN | $88.68 -1.54% -1.57% 1.8M twitter stocktwits trandingview |
Health Technology
 | | O: 1.2% H: 1.97% C: -3.69%
fda diagnostic companion therapy
Gainers vs Losers
67% 33%

Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M twitter stocktwits trandingview |
Finance
EGOX | $0.0515 43.06% 30.1% 330M twitter stocktwits trandingview |

OLB 4 | $0.33 -14.95% 25.53% 840K twitter stocktwits trandingview |
Technology Services
NVFY | $2.77 31.28% 23.83% 33M twitter stocktwits trandingview |
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M twitter stocktwits trandingview |
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M twitter stocktwits trandingview |
Distribution Services
INSG | $3.03 25.21% 20.13% 330K twitter stocktwits trandingview |
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K twitter stocktwits trandingview |
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M twitter stocktwits trandingview |

ASNS | $0.828 21.75% 17.86% 18K twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.